On April 25, 2023, the NMPA official website showed that KRRP's nimergolin tablets had passed the generic drug consistency evaluation. Among the approved nimergolin preparations, only KRRP's nimergolin tablets submitted a supplementary application for consistency evaluation and successfully became the first approved enterprise of the product, which is also the company's first approved product.

As a classic cerebrovascular drug, nimergoline's terminal sales in public medical institutions in China exceeded 1.3 billion yuan in 2021, a year-on-year increase of 28.31%. KRRP is a leading enterprise in the market for nimergolin preparations. The review of this variety helps to enhance the company's market competitiveness and strengthen our belief in continuously increasing research and development based on innovation. In May, the company once again received good news that all the invention and utility model patents applied for by KRRP in 2022 have been approved.